【摘要】 动脉粥样硬化性心血管疾病(ASCVD)已成为全球居民死亡的主要原因。人体血脂紊乱，特别是低密度脂蛋白胆固醇(LDL-C)的增加，是影响动脉粥样硬化(AS)发生发展的最重要因素。前蛋白转化酶枯草溶菌素9(PCSK9)通过与低密度脂蛋白受体(LDLR)的结合，减少LDLR对血清LDL-C的清除。PCSK9抑制剂，如Alirocumab、Evolocumab和Inclisiran等，可阻止LDLR降解，促进LDL-C的清除，为改善临床脂质代谢和ASCVD的预后提供了新方法。本文系统性地回顾了PCSK9及其抑制剂的发现和作用机制，并对近年来PCSK9抑制剂与心血管事件关系的临床数据作一综述。更多还原

【Abstract】 Atherosclerotic cardiovascular disease(ASCVD) has become the leading cause of death in global population. Lipid disorders, especially increase of low-density lipoprotein cholesterol(LDL-C), is the most important factor affecting the development of atherosclerosis(AS). The proprotein convertase subtilisin/kexin type 9(PCSK9) can reduce the clearance of serum LDL-C by binding to low density lipoprotein receptor(LDLR). PCSK9 inhibitors, such as alirocumab, evolocumab, inclisiran, can prevent LDLR degradation and promote LDL-C clearance, which provides a new approach to improve metabolism of clinical lipid and prognosis of ASCVD. This article systematically reviews the discovery and mechanism of PCSK9 and its inhibitors, and presents a review of recent clinical data on the relationship between PCSK9 inhibitors and cardiovascular events.更多还原